This publication is provided for historical reference only and the information may be out of date.
Focus of Research for Clinicians
As an update to a 2006 report, a systematic review of 273 clinical studies published between January 2005 and January 2011 examined the comparative effectiveness, benefits, and adverse effects of analgesics and the supplements glucosamine and chondroitin for osteoarthritis. The review did not include studies on opioid medications or nonpharmacological interventions for osteoarthritis. The full report, listing all studies, is available at www.effectivehealthcare.ahrq.gov/analgesicsupdate.cfm. This summary, based on the full report of research evidence, is provided to inform discussions with patients of options and to assist in decisionmaking along with a patient's values and preferences. However, reviews of evidence should not be construed to represent clinical recommendations or guidelines.
Background
Osteoarthritis is a chronic condition involving degradation of cartilage within the joints. It is the most common form of arthritis and is more common in older people. It is associated with pain, substantial disability, and reduced quality of life.
Common oral medications for osteoarthritis studied in this review were nonopioid medications, including selective and nonselective nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, salsalate, acetaminophen, over-the-counter dietary supplements (glucosamine and chondroitin), and topical agents (NSAIDs and rubefacients, including capsaicin). The over-the-counter supplements glucosamine and chondroitin have grown in popularity; however, these are not regulated by the United States Food and Drug Administration (FDA).
NSAIDs block cyclooxygenase (COX) enzymes, particularly COX-1 and COX-2. An important role of COX-1 is to mediate the mucosal protection of the gastrointestinal (GI) mucosa, and COX-2 mediates effects on pain and inflammation.
By blocking COX-2 enzymes, NSAIDs decrease pain and inflammation. Nonselective NSAIDs block both COX-1 and COX-2. NSAIDs that block COX-1 can cause GI adverse effects, including bleeding. Selective or partially selective (in vitro) NSAIDs block mostly COX-2 and thus should be safer with regard to GI adverse effects. However, it is unclear if partially selective NSAIDs are truly different from nonselective NSAIDs because COX-2 selectivity may be lost at higher doses. The effects of in vitro COX-2 selectivity on clinical outcomes are uncertain.
Conclusion
When analgesics are compared to each other, none appears to offer greater benefits relative to adverse effects at this time. Trade-offs between benefits and adverse effects appear to differ across analgesics, increasing the need to consider individual patient priorities when choosing among these medications. No significant analgesic differences were found in the benefits offered by NSAIDs; however, differences in GI adverse effects must be balanced with associated cardiovascular (CV) risks. Evidence suggests that age, comorbid conditions, and concomitant medication are key considerations affecting decisionmaking.
The evidence concerning the use of glucosamine and chondroitin appears unresolved and may not directly apply to unregulated products available in the United States. There is evidence that the topical NSAID diclofenac works as effectively as the oral agent.
Clinical Bottom Line
Gaps in Knowledge
- Most of the clinical trials reviewed were “efficacy” trials conducted in ideal settings and among selected populations. “Pragmatic” trials that allow fexible dosing or medication switches and other clinical trials of effectiveness would be valuable for learning the outcomes of different analgesic interventions in real-world settings.
- More evidence is needed to assess the comparative CV risks and GI benefits associated with different COX-2 selective NSAIDs.
- The risks associated with selective COX-2 inhibitors need better assessment for the effects of dose and duration.
- More evidence is needed to determine the CV safety of nonselective NSAIDs.
- Evidence is lacking to determine the GI and CV safety of full-dose aspirin, salsalate, or acetaminophen when compared with nonaspirin NSAIDs or placebo.
- The effects of alternative dosing strategies such as intermittent dosing or drug holidays have not been well studied.
- Most trials showing therapeutic benefits from glucosamine were conducted with pharmaceutical-grade glucosamine not available in the United States. Therefore, the results of these trials may not be applicable to currently available over-the-counter preparations. More evidence is needed comparing currently available over-the-counter preparations with oral NSAIDs, as these over-the-counter preparations are likely to remain available even if the FDA approves a pharmaceutical-grade glucosamine.
- More evidence is needed to evaluate the comparative risks of serious CV and GI adverse effects for oral NSAIDs versus topical NSAIDs.
What To Discuss With Your Patients
- The importance of managing osteoarthritis-related pain and inflammation for improving quality of life and function.
- The potential benefits and adverse effects associated with different types of analgesics based on the characteristics of the individual patient.
- Individual patient values and preferences when considering the trade-offs between benefits and adverse effects of each treatment option.
- Information on symptoms that indicate GI and/or CV adverse effects, and directions for when these symptoms should be reported.
Resource for Patients
Managing Osteoarthritis Pain With Medicines, A Review of the Research for Adults is a free companion to this clinician research summary. It can help patients talk with their health care professionals about the options for treating their osteoarthritis with analgesics. It provides:
- Information about the symptoms of osteoarthritis.
- Descriptions of the different analgesics.
- Simplified summaries of the research on benefits and adverse effects for each analgesic.
- Questions for patients to ask their doctor.
Ordering Information
For electronic copies of Managing Osteoarthritis Pain With Medicines, A Review of the Research for Adults (AHRQ Pub. No. 11(12)-EHC076-A), this clinician research summary, and the full systematic review, visit www.effectivehealthcare. ahrq.gov/analgesicsupdate.cfm. To order free print copies, call the AHRQ Publications Clearinghouse at 800-358-9295.
Source
The information in this guide is based on Comparative Effectiveness and Safety of Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review, Comparative Effectiveness Review No. 38, prepared by the Oregon Evidence-based Practice Center under Contract No. HHSA-290-2007-10057-I for the Agency for Healthcare Research and Quality, October 2011. Available at: www. effectivehealthcare.ahrq.gov/analgesicsupdate.cfm. This clinician research summary was prepared by the John M. Eisenberg Center for Clinical Decisions and Communications Science at Baylor College of Medicine, Houston, TX.
Publication Details
Author Information and Affiliations
Authors
John M Eisenberg Center for Clinical Decisions and Communications Science1.Affiliations
Publication History
Issued: February 15, 2012.
Copyright
Publisher
Agency for Healthcare Research and Quality (US), Rockville (MD)
NLM Citation
John M Eisenberg Center for Clinical Decisions and Communications Science. Analgesics for Osteoarthritis. 2012 Feb 15. In: Comparative Effectiveness Review Summary Guides for Clinicians [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007-.